Cytek Biosciences Inc (NAS:CTKB)
$ 6.39 -0.14 (-2.14%) Market Cap: 841.13 Mil Enterprise Value: 572.72 Mil PE Ratio: 0 PB Ratio: 2.20 GF Score: 60/100

Cytek Biosciences Inc Corporate Analyst Meeting Transcript

Jun 22, 2022 / 01:00PM GMT
Release Date Price: $10.4 (+4.52%)
Wenbin Jiang
Cytek Biosciences, Inc. - President, CEO & Chairman of the Board

Good morning, everyone. Welcome to our first Analyst Day. And many of you, we actually probably have met during the last 12 months, remotely, virtually through Zoom. This is the first time we will be able to meet in person. Really glad to be here.

And last 12 months, and really, it has been an exciting journey for Cytek. We are very, very happy to have you together riding with us. Over this path, although the market has been up and down, Cytek has continued to grow, to expand according to what we have told you, what we are going to do, according to our plan.

Company have been doing very well. And -- but on the other hand, so our communications, many of you have been asking us, what Cytek is? As to what kind of business are you having? Because you are all very familiar with the generic space, and there are many companies of our size in that part of the business. However, Cytec, in fact, is the only company in the cell analysis space, a public company, independent, all of our competitors in this business is

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot